Preclinical
April 17, 2023
AACR
ZW251, a novel Glypican 3-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
Madera et al.
Preclinical
April 17, 2023
AACR
ZW171, a T Cell-Engaging, Bispecific Antibody for the Treatment of Mesothelin-Expressing Solid Tumors
Afacan et al.
Preclinical
April 17, 2023
AACR
TriTCE CPI, Next Generation Trispecific T Cell Engagers with Integrated Checkpoint Inhibition (CPI) for the Treatment of Solid Tumors
Poffenberger et al.
Preclinical
April 17, 2023
AACR
ZW270, A Conditionally Masked IL-12 Cytokine Fusion Protein Displaying Potent Anti-tumour Activity Absent of Systemic Toxicity
Escalante et al.
Preclinical
April 17, 2023
AACR
ZW191, a novel FRα-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
Lawn et al.
Preclinical
April 17, 2023
AACR
Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker
stability and the primacy of payload delivery
Colombo et al.
Preclinical
April 17, 2023
AACR
ZW220, a novel NaPi2b-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
Hernández et al.
Preclinical
March 15, 2023 - March 16, 2023
World ADC London
ZW191: A Potential Best-in-Class TOPO1i ADC for Treatment of FRα-Expressing Solid Tumors
Sam Lawn
Preclinical
December 5, 2022
Antibody Engineering & Therapeutics Conference
Novel IgG1 Cysteine Insertion Sites Enable Site-Specific Conjugation and Precise Control of Drug to Antibody Ratio
Das et al.
Preclinical
November 10, 2022
SITC
Optimization of purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs)
Garnett et al.
Preclinical
October 13, 2022
Cancer Cell
The therapeutic window of antibody drug conjugates: A dogma in need of revision
Colombo et al.
Preclinical
September 9, 2022
World ADC San Diego
Zymeworks Topoisomerase 1 Inhibitor ADC Platform: From Concept to Pipeline
Barnscher et al.
